$PMCB Contract Research Organization Voted Australia’s Favorite CRO for 2015

PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box^®, today reported that Clinical Network Services (CNS), the Contract Research Organization (CRO) chosen by PharmaCyte Biotech to prepare for and conduct its upcoming Phase 2b clinical trial in pancreatic cancer, has been voted Australia’s favorite CRO for 2015.

The award was presented to CNS at the 2015 ARCS Scientific Congress and was based on votes from local investigational study sites and from local and international sponsors of clinical trials. ARCS Australia Ltd., previously known as the Association of Regulatory and Clinical Scientists, is a professional development organization for those working in the development of disease therapies.

Gabrielle McKee, CNS’ Chief Operating Officer, said of the award, “CNS is proud and honored to have won this award. As a company, CNS has always been committed to maintaining a positive culture focused on how we interact with each other, our clients and importantly the wonderful clinicians, coordinators and pharmacists who are at the forefront of delivering our trials to patients.”

PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, offered the company’s congratulations, stating, “All of us at PharmaCyte Biotech would like to offer our sincerest congratulations to those at CNS in winning the ARCS award as Australia’s Favorite CRO for 2015. When we were evaluating CRO’s that might best assist us in our Phase 2b clinical trial in those with advanced pancreatic cancer in Australia, it became evident early on in that process that CNS was one of Australia’s leading CROs.”

“This evaluation has been proven correct by the excellent and most professional manner in which CNS’ personnel have interacted with us since our contracts with CNS were signed. The ARCS award to CNS bolters our already high confidence that CNS will prove to be a valuable partner as we develop our treatment for one of the deadliest cancers.”

Russell Neal, Managing Director of CNS, commented, “It has been an exciting year or so for all of us at CNS, and to this receive recognition from ARCS is testament to the exceptional hard work and commitment everyone at CNS brings to our client’s programs. We’re very proud of our growing reputation as it presents us with opportunities to work with cutting edge technologies, such as PharmaCyte Biotech’s exciting Cell-in-a-Box^® and their wonderfully talented team.”

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box^®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials.

In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.

PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box^® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to PharmaCyte Biotech or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte Biotech, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte Biotech’s intellectual property and PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte Biotech does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com